This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (86)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Immunologic Disorders  • Neurology  • Alert me on articles by topic

A Prospective Study

Alberto Ascherio, MD,DrPH; Kassandra L. Munger, MSc; Evelyne T. Lennette, PhD; Donna Spiegelman, ScD; Miguel A. Hernán, MD,DrPH; Michael J. Olek, DO; Susan E. Hankinson, ScD; David J. Hunter, ScD

JAMA. 2001;286:3083-3088.

Context  Epidemiological studies suggest an association between infection with Epstein-Barr virus (EBV) and risk of multiple sclerosis (MS).

Objective  To determine whether elevation in serum antibody titers to EBV viral capsid antigen (VCA), nuclear antigens (EBNA, EBNA-1, and EBNA-2), and diffuse and restricted early antigen (EA-D and EA-R) as well as to cytomegalovirus (CMV) precede the occurrence of MS.

Design, Setting, and Subjects  Prospective, nested case-control study. Of 62 439 women participating in the Nurses' Health Study (aged 30-55 years in 1976) and Nurses' Health Study II (aged 25-42 years in 1989) who gave blood samples in 1989-1990 and 1996-1999, respectively, and were followed up through 1999, 144 women with definite or probable MS and 288 healthy age-matched controls were included in the analysis.

Main Outcome Measure  Serum antibody titers to the specific EBV and CMV antigens, compared between cases and controls.

Results  We documented 18 cases of MS with blood collected before disease onset. Compared with their matched controls, these women had higher serum geometric mean titers (GMTs) of antibodies to EBV but not CMV. Elevations were significant for antibodies to EBNA-1 (GMT, 515 vs 203; P = .03), EBNA-2 (GMT, 91 vs 40; P = .01), and EA-D (15.9 vs 5.9; P = .04). The strongest association was found for antibodies to EBNA-2; a 4-fold difference in titers was associated with a relative risk (RR) of MS of 3.9 (95% confidence interval [CI], 1.1-13.7). The corresponding RRs were 1.6 (95% CI, 0.7-3.7) for VCA, 2.5 (95% CI, 1.0-6.3) for EBNA, 1.8 (95% CI, 1.0-3.1) for EA-D, and 1.0 (95% CI, 0.6-1.7) for CMV. Significant but generally weaker elevations in anti-EBV antibodies were also found in analyses of 126 cases of MS with blood collected after disease onset and their matched controls.

Conclusions  Our results support a role of EBV in the etiology of MS.

Author Affiliations: Departments of Nutrition (Dr Ascherio and Ms Munger), Epidemiology (Drs Ascherio, Spiegelman, Hernán, Hankinson, and Hunter), and Biostatistics (Dr Spiegelman), Harvard School of Public Health, Center for Neurological Diseases–Multiple Sclerosis Unit (Dr Olek), and Channing Laboratory, Department of Medicine (Drs Hankinson and Hunter), Harvard Medical School and Brigham and Women's Hospital, Boston, Mass; and Virolab Inc (Dr Lennette), Berkeley, Calif.

RELATED ARTICLES

Viruses and Multiple Sclerosis
Donald H. Gilden
JAMA. 2001;286(24):3127-3129.
EXTRACT | FULL TEXT  

December 26, 2001
JAMA. 2001;286(24):3179-3180.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis
De Jager et al.
Neurology 2008;70:1113-1118.
ABSTRACT | FULL TEXT  

Could vitamin D be the answer to multiple sclerosis?
Broadley
Mult Scler 2007;13:825-826.
 

Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function
Lucas et al.
Mult Scler 2007;13:827-839.
ABSTRACT  

Variation in the Epstein-Barr virus receptor, CR2, and risk of multiple sclerosis
Simon et al.
Mult Scler 2007;13:947-948.
 

Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?
Lunemann et al.
J. Virol. 2007;81:6777-6784.
FULL TEXT  

Natalizumab for Multiple Sclerosis
Ransohoff
NEJM 2007;356:2622-2629.
FULL TEXT  

Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals
Nielsen et al.
Mult Scler 2007;13:420-423.
ABSTRACT  

Multiple Sclerosis After Infectious Mononucleosis
Nielsen et al.
Arch Neurol 2007;64:72-75.
ABSTRACT | FULL TEXT  

Cigarette smoking and autoimmune disease: what can we learn from epidemiology?
Costenbader and Karlson
Lupus 2006;15:737-745.
ABSTRACT  

Murine Vbeta3+ and Vbeta7+ T Cell Subsets Are Specific Targets for the HERV-K18 Env Superantigen.
Tai et al.
J. Immunol. 2006;177:3178-3184.
ABSTRACT | FULL TEXT  

Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis
Lunemann et al.
Brain 2006;129:1493-1506.
ABSTRACT | FULL TEXT  

Epstein-Barr Virus and Multiple Sclerosis: Evidence of Association From a Prospective Study With Long-term Follow-up
DeLorenze et al.
Arch Neurol 2006;63:839-844.
ABSTRACT | FULL TEXT  

Multiple sclerosis.
BLUMENTHAL
radtech 2006;77:309-321.
ABSTRACT | FULL TEXT  

Are multiple sclerosis patients risk-takers?
Hawkes
QJM 2005;98:895-911.
ABSTRACT | FULL TEXT  

Multiple sclerosis in Tayside, Scotland: detection of clusters using a spatial scan statistic
Donnan et al.
Mult Scler 2005;11:403-408.
ABSTRACT  

A randomized clinical trial of valacyclovir in multiple sclerosis
Friedman et al.
Mult Scler 2005;11:286-295.
ABSTRACT  

Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
Levin et al.
JAMA 2005;293:2496-2500.
ABSTRACT | FULL TEXT  

Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter
Opsahl and Kennedy
Brain 2005;128:516-527.
ABSTRACT | FULL TEXT  

Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis
Ponsonby et al.
JAMA 2005;293:463-469.
ABSTRACT | FULL TEXT  

Multiple sclerosis after infectious mononucleosis: record linkage study
Goldacre et al.
J. Epidemiol. Community Health 2004;58:1032-1035.
ABSTRACT | FULL TEXT  

Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication
Guerreiro-Cacais et al.
J. Gen. Virol. 2004;85:2767-2778.
ABSTRACT | FULL TEXT  

An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study
Sundstrom et al.
Neurology 2004;62:2277-2282.
ABSTRACT | FULL TEXT  

Epstein-Barr Virus in Pediatric Multiple Sclerosis
Alotaibi et al.
JAMA 2004;291:1875-1879.
ABSTRACT | FULL TEXT  

The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark
Li et al.
Neurology 2004;62:726-729.
ABSTRACT | FULL TEXT  

Risk of multiple sclerosis in nurse anaesthetists
Stenager et al.
Mult Scler 2003;9:427-428.
 

Epstein-Barr Virus and Risk of Multiple Sclerosis--Reply
Levin et al.
JAMA 2003;290:193-193.
FULL TEXT  

The immune response against herpesvirus is more prominent in the early stages of MS
Villoslada et al.
Neurology 2003;60:1944-1948.
ABSTRACT | FULL TEXT  

The risk of multiple sclerosis in nurses: a population-based epidemiological study
Stenager et al.
Mult Scler 2003;9:299-301.
ABSTRACT  

Epstein-Barr virus may increase risk of multiple sclerosis
Gottlieb
BMJ 2003;326:731-731.
FULL TEXT  

Multiple Sclerosis and Epstein-Barr Virus
Levin et al.
JAMA 2003;289:1533-1536.
ABSTRACT | FULL TEXT  

Is Multiple Sclerosis Linked to EBV?
JWatch Infect. Diseases 2002;2002:7-7.
FULL TEXT  

Viruses and Multiple Sclerosis
Gilden
JAMA 2001;286:3127-3129.
FULL TEXT